MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 596977 | Name: Pentetreotide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pentetreotide is an indium-labelled somatostatin analog for imaging of somatostatin receptor positive tumours; OctreoScan is tradename for indium In 111 pentetreotide.

Chemical Structure

Pentetreotide
Pentetreotide
CAS#138661-02-6

Theoretical Analysis

MedKoo Cat#: 596977

Name: Pentetreotide

CAS#: 138661-02-6

Chemical Formula: C63H87N13O19S2

Exact Mass: 1393.5683

Molecular Weight: 1394.58

Elemental Analysis: C, 54.26; H, 6.29; N, 13.06; O, 21.80; S, 4.60

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Pentetreotide; SDZ 215-811; SDZ 215-811s; DTPA-octreotide; DTPA-SMS;
IUPAC/Chemical Name
N-(2-((2-(Bis(carboxymethyl)amino)ethyl)(carboxymethyl)amino)ethyl)-N-(carboxymethyl)glycyl-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (3-8)-disulfide
InChi Key
CNLWNYCFDMAZCB-HUVROIHYSA-N
InChi Code
1S/C63H87N13O19S2/c1-37(78)48(34-77)70-62(94)50-36-97-96-35-49(71-58(90)45(25-39-13-5-3-6-14-39)66-51(80)29-75(31-53(83)84)23-21-74(30-52(81)82)22-24-76(32-54(85)86)33-55(87)88)61(93)68-46(26-40-15-7-4-8-16-40)59(91)69-47(27-41-28-65-43-18-10-9-17-42(41)43)60(92)67-44(19-11-12-20-64)57(89)73-56(38(2)79)63(95)72-50/h3-10,13-18,28,37-38,44-50,56,65,77-79H,11-12,19-27,29-36,64H2,1-2H3,(H,66,80)(H,67,92)(H,68,93)(H,69,91)(H,70,94)(H,71,90)(H,72,95)(H,73,89)(H,81,82)(H,83,84)(H,85,86)(H,87,88)/t37-,38-,44+,45-,46+,47-,48-,49+,50+,56+/m1/s1
SMILES Code
C[C@H]([C@H](NC([C@@H]1CSSC[C@@H](C(N[C@H](C(N[C@@H](C(N[C@H](C(N[C@H](C(N1)=O)[C@H](O)C)=O)CCCCN)=O)Cc(c[nH]2)c3c2cccc3)=O)Cc4ccccc4)=O)NC([C@H](NC(CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC(O)=O)=O)Cc5ccccc5)=O)=O)CO)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,394.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Mori H, Nakajima K, Kadomoto S, Mizokami A, Ikeda H, Wakabayashi H, Kinuya S. Imaging Somatostatin Receptor Activity in Neuroendocrine-differentiated Prostate Cancer. Intern Med. 2018 Jun 6. doi: 10.2169/internalmedicine.0630-17. [Epub ahead of print] PubMed PMID: 29877274. 2: Bahougne T, Romanet P, Mohamed A, Caselles K, Cuny T, Barlier A, Niccoli P. Functioning Mediastinal Paraganglioma Associated with a Germline Mutation of von Hippel-Lindau Gene. J Clin Med. 2018 May 23;7(6). pii: E116. doi: 10.3390/jcm7060116. PubMed PMID: 29789510. 3: Matsusaka Y, Nakahara T, Kurihara I, Iwabuchi Y, Jinzaki M. Bilateral Adrenal Hyperplasia Due to Adrenocorticotropic Hormone-Secreting Esthesioneuroblastoma on FDG PET and 111In-Pentetreotide Scintigraphy. Clin Nucl Med. 2018 Jun;43(6):452-453. doi: 10.1097/RLU.0000000000002081. PubMed PMID: 29659387. 4: Paquet M, Gauthé M, Zhang Yin J, Nataf V, Bélissant O, Orcel P, Roux C, Talbot JN, Montravers F. Diagnostic performance and impact on patient management of (68)Ga-DOTA-TOC PET/CT for detecting osteomalacia-associated tumours. Eur J Nucl Med Mol Imaging. 2018 Mar 12. doi: 10.1007/s00259-018-3971-x. [Epub ahead of print] PubMed PMID: 29532101. 5: Del Gatto V, Bima C, Chiloiro S, Giampietro A, Bianchi A. Use of 111In-pentetreotide scintigraphy for diagnosis and management of resistant macroprolactinoma. Endocrine. 2018 Jun;60(3):532-534. doi: 10.1007/s12020-017-1486-z. Epub 2017 Dec 6. PubMed PMID: 29214441. 6: Thuillier P, Bourhis D, Robin P, Keromnes N, Schick U, Le Roux PY, Kerlan V, Chaumet-Riffaud P, Salaün PY, Abgral R. Clinical Validation of a Pixon-Based Reconstruction Method Allowing a Twofold Reduction in Planar Images Time of 111In-Pentetreotide Somatostatin Receptor Scintigraphy. Front Med (Lausanne). 2017 Aug 30;4:143. doi: 10.3389/fmed.2017.00143. eCollection 2017. PubMed PMID: 28913338; PubMed Central PMCID: PMC5583596. 7: Spanu A, Schillaci O, Piras B, Calvisi DF, Falchi A, Danieli R, Nuvoli S, Dore F, Madeddu G. Non-functioning gastroenteropancreatic (GEP) tumors: a (111)In-Pentetreotide SPECT/CT diagnostic study. Am J Nucl Med Mol Imaging. 2017 Sep 1;7(4):181-194. eCollection 2017. PubMed PMID: 28913157; PubMed Central PMCID: PMC5596321. 8: Smit Duijzentkunst DA, Kwekkeboom DJ, Bodei L. Somatostatin Receptor 2-Targeting Compounds. J Nucl Med. 2017 Sep;58(Suppl 2):54S-60S. doi: 10.2967/jnumed.117.191015. Review. PubMed PMID: 28864613. 9: Inoue Y, Abe Y, Kikuchi K, Miyatake H, Watanabe A. Effects of Different Containers on Radioactivity Measurements using a Dose Calibrator with Special Reference to (111)In and (123)I. Kaku Igaku. 2017;54(1):545-549. doi: 10.18893/kakuigaku.tr.1701. Japanese. PubMed PMID: 28804109. 10: Tuzcu SA, Pekkolay Z, Kılınç F, Tuzcu AK. (68)Ga-DOTATATE PET/CT Can Be an Alternative Imaging Method in Insulinoma Patients. J Nucl Med Technol. 2017 Sep;45(3):198-200. doi: 10.2967/jnmt.117.192708. Epub 2017 Aug 10. PubMed PMID: 28798227. 11: Hasegawa S, Kobayashi N, Tokuhisa M, Goto A, Takano S, Takada Y, Kaneta T, Mori R, Matsuyama R, Endo I, Yamanaka S, Nakajima A, Inoue T, Ichikawa Y. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors. Digestion. 2017;96(1):13-20. doi: 10.1159/000470838. Epub 2017 Jun 14. PubMed PMID: 28609761. 12: Cuccurullo V, Prisco MR, Di Stasio GD, Mansi L. Nuclear Medicine in Patients with NET: Radiolabeled Somatostatin Analogues and their Brothers. Curr Radiopharm. 2017;10(2):74-84. doi: 10.2174/1874471010666170323115136. Review. PubMed PMID: 28332450. 13: Graham MM, Gu X, Ginader T, Breheny P, Sunderland JJ. (68)Ga-DOTATOC Imaging of Neuroendocrine Tumors: A Systematic Review and Metaanalysis. J Nucl Med. 2017 Sep;58(9):1452-1458. doi: 10.2967/jnumed.117.191197. Epub 2017 Mar 9. Review. Erratum in: J Nucl Med. 2017 Oct;58(10 ):1707. PubMed PMID: 28280220. 14: Cuccurullo V, Di Stasio GD, Mansi L. Radioguided surgery with radiolabeled somatostatin analogs: not only in GEP-NETs. Nucl Med Rev Cent East Eur. 2017;20(1):49-56. doi: 10.5603/NMR.2017.0003. Review. PubMed PMID: 28218348. 15: Zhang-Yin J, Dirand AS, Sasanelli M, Corrégé G, Peudon A, Kiffel T, Nataf V, Clerc J, Montravers F, Talbot JN. Equivalent Dose Rate 1 Meter from Neuroendocrine Tumor Patients Exiting the Nuclear Medicine Department After Undergoing Imaging. J Nucl Med. 2017 Aug;58(8):1230-1235. doi: 10.2967/jnumed.116.187138. Epub 2017 Feb 16. PubMed PMID: 28209907. 16: Vicente EM, Lodge MA, Rowe SP, Wahl RL, Frey EC. Simplifying volumes-of-interest (VOIs) definition in quantitative SPECT: Beyond manual definition of 3D whole-organ VOIs. Med Phys. 2017 May;44(5):1707-1717. doi: 10.1002/mp.12164. Epub 2017 Mar 28. PubMed PMID: 28207950; PubMed Central PMCID: PMC5462436. 17: Savelli G, Bnà C, Zambelli C, Illuminati S, Bonello L. An 111In-Pentetreotide Positive Sclerosing Pneumocytoma. Clin Nucl Med. 2017 Apr;42(4):282-284. doi: 10.1097/RLU.0000000000001544. PubMed PMID: 28166143. 18: Mannelli L, Monti S, Grieco V, Matesan M. Hepatic Lesions in a Cirrhotic Liver: Primary or Metastases? J Nucl Med Technol. 2017 Mar;45(1):50-52. doi: 10.2967/jnmt.116.183228. Epub 2017 Feb 2. PubMed PMID: 28154018. 19: Giovacchini G, Giovannini E, Riondato M, Ciarmiello A. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer. Curr Radiopharm. 2017;10(1):6-15. doi: 10.2174/1874471009666161229123126. Review. PubMed PMID: 28034291. 20: Tshori S, Bocher M, Yuzefovich B, Rubinstein R, Gross DJ, Fraenkel M, Krausz Y. Diagnostic Computed Tomography Coregistration With In-111-DTPA-Octreotide Single Photon Emission Tomography/Low-Dose Computed Tomography. J Comput Assist Tomogr. 2017 May/Jun;41(3):499-504. doi: 10.1097/RCT.0000000000000527. PubMed PMID: 27879526.